Some patients will present with symptoms of recurrent disease; recurrence may also be discovered during surveillance in the post-treatment period. Prompt referral for management by a multidisciplinary team is recommended to achieve the best outcomes for anyone with recurrent disease.

Re-biopsy should be considered if feasible. Perform molecular and immunological biomarker testing to inform further therapies (or, if available, blood samples for circulating tumour DNA [ctDNA] molecular testing).